Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cc-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 0.71 |
| ▸ | PRKDC known ✓ | P78527 | 1/20 | 0.71 |
| ▸ | RPTOR | Q8N122 | 17/20 | 0.71 |
| ▸ | MLST8 | Q9BVC4 | 17/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.71 |
| ▸ | CSF1R | P07333 | 1/20 | 0.71 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cc-115 SCHEMBL135765 | 0.99 | MTOR (0.72) | MTORRPTORMLST8PIK3CACSF1R | |
| Cc-115 SCHEMBL29522125 | 0.99 | MTOR (0.72) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522183 | 0.88 | MTOR (0.74) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138204 | 0.88 | MTOR (0.74) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL16186757 | 0.88 | MTOR (0.57) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138359 | 0.87 | MTOR (0.55) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL136142 | 0.85 | MTOR (0.75) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522078 | 0.85 | MTOR (0.75) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522319 | 0.85 | MTOR (0.76) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL137471 | 0.85 | MTOR (0.76) | MTORRPTORMLST8PIK3CACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091021-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-2493472-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-3091021-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9079900-B2 | Methods of synthesis and purification of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140155593-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-8569494-B2 | Methods of synthesis and purification of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | disclosed |
| EP-2493472-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| WO-2011053518-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PRKDC 4783/4885RPTOR 478/4885 |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PRKDC 4783/4885RPTOR 478/4885 |
| US-20140155593-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885PRKDC 4783/4885RPTOR 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.